---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-22-000061"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:36:09.334684+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech Q3 net loss $29.9M; B-VEC BLA with Priority Review accepted, PDUFA Feb 17, 2023

## Summary
- Cash and investments $407M at quarter end; net loss $29.9M ($1.17 per share) vs $15.6M loss in Q3 2021.
- FDA accepted B-VEC BLA for dystrophic epidermolysis bullosa with Priority Review; PDUFA target Feb 17, 2023.
- No Advisory Committee meeting or REMS needed after mid-cycle review; EMA Pediatric Committee gave positive opinion.
- R&D spent $11.5M (Q3 2022); pipeline: KB407 (CF) IND accepted, dosing starts Q4 2022; KB105, KB104, KB301 advancing.

## SEC filing metadata
- accession: 0001711279-22-000061
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127922000061/0001711279-22-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127922000061/krys-20221107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-22-000061
- JSON: https://secwatch.observer/filing/0001711279-22-000061.json
- Plain text: https://secwatch.observer/filing/0001711279-22-000061.txt

## Key facts
- Earnings Releases
  Krystal Biotech, Inc. reported the third quarter ended September 30, 2022 results: net income $29.9 million, EPS $(1.17) per common share (basic and diluted).
  - Period: the third quarter ended September 30, 2022
  - Net income: $29.9 million
  - EPS: $(1.17) per common share (basic and diluted)
  - Result: reported results
  source text: Net losses for the quarters ended September 30, 2022 and 2021 were $29.9 million and $15.6 million, or $(1.17) and $(0.70), respectively, per common share (basic and diluted).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711279/000171127922000061/0001711279-22-000061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.